Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trialJeffrey A. Cohen, Ludwig Kappos, Gıancarlo Comı et al.|The Lancet Neurology|2019Cited by 279
Ocular Monkeypox — United States, July–September 2022Shama Cash‐Goldwasser, James T. Lee, Andrea M. McCollum et al.|MMWR Morbidity and Mortality Weekly Report|2022Cited by 95